EUVIMEDEUVIMED entdecken
Crossref

Effects of 2,3‐DPG knockout on SCD phenotype in Townes SCD model mice

Amey Barakat, Reema Jasuja, Lindsay Tomlinson, Zane Wenzel, Lila Ramaiah, Betty A Petterson, Brendon Kapinos, Anagha Sawant, Vicente Pagan, Nathanael Lintner, Denise Field, Youngwook Ahn iD und 1 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.27082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Amey Barakat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Rare Disease Research Unit, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3‐DPG by activation of Pyruvate Kinase‐R are currently being evaluated in SCD patients. In this study, we genetically engineered a mouse lacking 2,3‐DPG on the Townes SCD mouse model background and evaluated the effects of 2,3‐DPG loss on disease pathology. Animals lacking 2,3‐DPG showed improvements in hematological markers and reductions in RBC sickling relative to native Townes mice, however, minimal difference in organ damage was observed in 2,3‐DPG deficient mice compared to native Townes animals. When animals lacking 2,3‐DPG were dosed with a compound designed to increase hemoglobin oxygen affinity, oxygen delivery related toxicity was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellAdultHumansMiceAnimals2,3-DiphosphoglycerateHemoglobinsPhenotypeOxygen

Substanzen

2,3-DiphosphoglycerateHemoglobinsOxygen

Autor:innen und Institutionen

  • Rare Disease Research Unit, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Drug Safety Research and Development, Worldwide Research, Development, and Medical, Pfizer Inc, Groton, Connecticut, USA.
  • Discovery Sciences, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Biomedicine Design, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Medicine Design, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Target Sciences, Worldwide Research, Development, and Medical, Pfizer Inc, Cambridge, Massachusetts, USA.

ORCID-Profile: Youngwook Ahn, Kelly M Knee

Zitieren

APA

Barakat, A., Jasuja, R., Tomlinson, L., Wenzel, Z., Ramaiah, L., Petterson, B. A., Kapinos, B., Sawant, A., Pagan, V., Lintner, N., Field, D., Ahn, Y., & Knee, K. M. (2023). Effects of 2,3‐DPG knockout on SCD phenotype in Townes SCD model mice. American Journal of Hematology. https://doi.org/10.1002/ajh.27082

Vancouver

Barakat A, Jasuja R, Tomlinson L, Wenzel Z, Ramaiah L, Petterson BA, et al. Effects of 2,3‐DPG knockout on SCD phenotype in Townes SCD model mice. American Journal of Hematology. 2023. doi:10.1002/ajh.27082

BibTeX
@article{Barakat2023,
  author = {Barakat, Amey and Jasuja, Reema and Tomlinson, Lindsay and Wenzel, Zane and Ramaiah, Lila and Petterson, Betty A and Kapinos, Brendon and Sawant, Anagha and Pagan, Vicente and Lintner, Nathanael and Field, Denise and Ahn, Youngwook and Knee, Kelly M},
  title = {Effects of 2,3‐DPG knockout on SCD phenotype in Townes SCD model mice},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.27082}
}
Kostenlos starten →